Zymeworks lands $250M milestone as Ziihera wins first-line cancer approval
What's the deal? Zymeworks has triggered a $250 million milestone payment from Jazz Pharmaceuticals after the United States Food and Drug Administration approved two Ziihera regimens for first-line treatment of unresectable, locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The decision moves zanidatamab-hrii into a substantially larger treatment setting.
What does the drug do? Zanidatamab is a bispecific HER2-targeted antibody discovered and engineered by Zymeworks. Unlike conventional antibodies, it binds two distinct epitopes on the same HER2 protein, potentially increasing receptor clustering, internalisation and immune-mediated tumour-cell killing.
What changed? The approval covers Ziihera with Tevimbra plus chemotherapy for HER2-positive tumours classified IHC 3+ or IHC 2+/ISH+, regardless of PD-L1 status. A second regimen, Ziihera with chemotherapy alone, was cleared for HER2 IHC 3+ tumours.
Why now? This is the second US approval for zanidatamab in under two years, after its earlier clearance in previously treated HER2-positive biliary tract cancer. Jazz had said it was ready to launch in the first-line setting immediately, so the commercial transition can begin quickly.
By the numbers. In the Phase 3 HERIZON-GEA-01 trial, which enrolled more than 900 previously untreated patients, median progression-free survival reached 12.4 months with zanidatamab plus tislelizumab and chemotherapy, against 8.1 months for trastuzumab plus chemotherapy. The zanidatamab and chemotherapy doublet also delivered 12.4 months.
How big is the market? Gastroesophageal adenocarcinoma spans cancers of the stomach, gastroesophageal junction and oesophagus, and roughly 20% of patients have HER2-positive disease. More than 31,000 new stomach cancer cases are diagnosed annually in the United States, and advanced HER2-positive disease still carries substantial mortality.
The signal: For Zymeworks, the approval converts a closely watched regulatory catalyst into immediate cash and a potentially larger royalty stream, while giving Jazz a chance to expand Ziihera into a far bigger patient population.
Read more: business-news-today.com
Image credit: National Institutes of Health (NIH)
